Calvagone

Menu

Publications & Presentations

Peer-reviewed publications

Peer-reviewed publications involving the Calvagone team, ordered by publication date. Each title links to its PubMed record. This list was last reviewed in October 2026.

  1. Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.Delavenne X, et al. Haemophilia. 2026;32(5):1179-1187.
  2. Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.Lobet S, et al. Biomedicine & Pharmacotherapy. 2026;198:119242.
  3. From Radiocopper to Cold Copper: Mechanistic Modeling and Simulation to Define Clinical Response Criteria and Biomarkers for VTX-801 in Wilson Disease.Lindauer A, et al. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(1):e70153.
  4. Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations.Snoeck E, et al. Expert Review of Clinical Pharmacology. 2025;18(11):957-967.
  5. Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM.Lindauer A, et al. Journal of Clinical Pharmacology. 2025;65(3):350-360.
  6. Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®.Laveille C, et al. British Journal of Clinical Pharmacology. 2024;90(9):2256-2270.
  7. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.Brossard P, Laveille C. Rheumatology and Therapy. 2024;11(3):869-880.
  8. Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.Traver E, et al. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(6):982-993.
  9. Efficacy and safety of emapalumab in macrophage activation syndrome.De Benedetti F, et al. Annals of the Rheumatic Diseases. 2023;82(6):857-865.
  10. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.Jacqmin P, et al. British Journal of Clinical Pharmacology. 2022;88(5):2128-2139.
  11. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations.Henin E, et al. Advances in Therapy. 2021;38(10):5317-5332.
  12. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.Erken R, et al. Journal of Viral Hepatitis. 2021;28(12):1690-1698.
  13. Acute dose-response effect of coffee-derived chlorogenic acids on the human vasculature in healthy volunteers: a randomized controlled trial.Naylor LH, et al. American Journal of Clinical Nutrition. 2021;113(2):370-379.
  14. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.Pierrillas PB, et al. Investigational New Drugs. 2020;38(6):1796-1806.
  15. Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr.Schoemaker R, et al. CPT: Pharmacometrics & Systems Pharmacology. 2019;8(12):923-930.
  16. Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.Jolling K, et al. CPT: Pharmacometrics & Systems Pharmacology. 2019;8(7):460-468.
  17. Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease.Cuerq C, et al. Journal of Lipid Research. 2018;59(9):1640-1648.
  18. Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy.Lindauer A, et al. Clinical Pharmacokinetics. 2017;56(11):1403-1413.

Search PubMed for additional publications

Posters & conference abstracts (2022–2025)

Selected scientific contributions involving members of the Calvagone team. Records are grouped by conference year, with links to public abstracts and posters where available.

2025

  • Modeling Copper Kinetics in Wilson’s Disease: A Mechanistic Model to Guide Gene Therapy Andreas Lindauer, Bernard Benichou, Gloria González Aseguinolaza, Jean-Philippe Combal. Poster III-001 · PAGE 2025, Thessaloniki, Greece. Abstract
  • Sampling of parameter uncertainty in Campsis Nicolas Luyckx, Emilie Hénin-Devessiere, Andreas Lindauer. Poster III-011 · PAGE 2025, Thessaloniki, Greece. Abstract · Poster PDF
  • From hot to cold: Modeling radiocopper kinetics in Wilson’s Disease to simulate cold copper endpoints Andreas Lindauer, Bernard Benichou, Gloria González Aseguinolaza, Jean-Philippe Combal. Poster M-075 · ACoP 2025, Aurora, Colorado, USA. Abstract
  • Physiologically Based Pharmacokinetic (PBPK) model of two Probenecid formulations in human plasma and predictions in brain using OSP Suite Sajid Ali Shah, Emilie Hénin, Andreas Lindauer, E. Brillaud. Poster · OSP Community Conference, Vitry-sur-Seine, France, 29–30 September 2025.

2024

  • A Mini-Tutorial on Campsis: The R-Based PK/PD Simulation Suite Andreas Lindauer, Nicolas Luyckx, Erno van Schaick, Emilie Hénin, Stéphanie Blaizot, Sajid Ali Shah, Pierre-Alexandre Noguine, Christian Laveille. Poster II-105 · PAGE 2024, Rome, Italy. Abstract · Poster PDF
  • Model-Informed Precision Dosing of Tacrolimus in Lung Transplantation Early After Surgery Using Model-Predictive Control in the tdmore Framework Nicolas Luyckx, Andreas Lindauer, Robin Vos, Dirk Kuypers. Poster III-001 · PAGE 2024, Rome, Italy. Abstract · Poster PDF
  • Population Pharmacokinetic Modeling of Leriglitazone in Healthy Volunteers and Patients with Neuro-degenerative Disorders – Exploring dosing schedules in children with adrenoleukodystrophy via simulations Andreas Lindauer, Erno van Schaick, Pilar Pizcueta, Laura Rodríguez-Pascau, Marc Martinell. Poster IV-060 · PAGE 2024, Rome, Italy. Abstract
  • Population pharmacokinetics of MLT103 and determination of CYP2D6 polymorphism by mixture modelling Emilie Hénin, Catherine Guittet, Christian Laveille. Poster II-034 · PAGE 2024, Rome, Italy. Abstract
  • Interactive Pharmacometric Simulations and Model Exploration with e-Campsis Andreas Lindauer, Nicolas Luyckx, Erno van Schaick, Emilie Hénin-Devessiere, Sajid Ali Shah, Stéphanie Blaizot-Besse, Sarah Lobet, Pierre-Alexandre Noguine, Christian Laveille. Poster W-076 · ACoP 2024, Phoenix, Arizona, USA. Conference listing
  • An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite Andreas Lindauer and colleagues. Poster W-077 · ACoP 2024, Phoenix, Arizona, USA. Abstract and author details

2023

  • e-Campsis: a Shiny PK/PD model simulator based on Campsis Nicolas Luyckx, Andreas Lindauer, Erno Van Schaick, Emilie Hénin-Devessiere, Stéphanie Blaizot-Besse, Pierre-Alexandre Noguine, Christian Laveille. Poster III-35 · PAGE 2023, A Coruña, Spain. Abstract · Poster PDF
  • Long-term follow-up of patients administered emapalumab, an anti-interferon-γ monoclonal antibody, to treat macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (sJIA) F. De Benedetti and colleagues, including Christian Laveille. Conference abstract · EULAR 2023. Annals of the Rheumatic Diseases. 2023;82:110–111. Bibliographic record

2022

  • Campsis: A generic, easy-to-use and intuitive PK/PD simulation platform based on R packages RxODE and mrgsolve Nicolas Luyckx, Andreas Lindauer, Erno Van Schaick, Emilie Hénin, Stéphanie Blaizot, Pierre-Alexandre Noguine, Christian Laveille. Poster I-32 · PAGE 2022, Ljubljana, Slovenia. Abstract · Poster PDF · Calvagone archive

Conference talks, tutorials & workshops (2024–2026)

Scientific talks and teaching contributions. Programme links document scheduled participation; workshop and tutorial entries are distinguished from research posters.

2026

  • Modeling radiocopper kinetics in Wilson’s disease to support the development of a novel gene therapy Andreas Lindauer. Oral communication — programme listing · Modelbio 2026, Valencia, Spain, 13 February 2026. Programme
  • PK/PD & QSP simulations with e-Campsis desktop Calvagone. Hands-on workshop — programme listing · PAGE satellite meeting, Dubrovnik, Croatia, 2 June 2026. Workshop programme

2025

  • Introduction to e-Campsis – a user-friendly interface for PK/PD/QSP simulations Andreas Lindauer. Tutorial · Modelbio 2025, Santiago de Compostela, Spain. Programme

2024

  • Effective Simulations to Support Communication and Decision-Making in Drug Development Andreas Lindauer. Oral communication · Modelbio 2024, Alicante, Spain. Programme
  • PKPD for Time to event or categorical events Emilie Hénin. Invited teaching contribution · GMP Pharmacokinetics Masterclass, France, January 2024.

Earlier posters & presentations

Browse our conference archive from before 2022.